

Thanks to the non conditioning contribution of:






WORKING ITALIAN SUMMIT ON PRECISION MEDICINE

Presidents: Giuseppe Curigliano and Paolo Marchetti

19th - 20th April 2024

Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome



Rational

Personalizing cancer medicine depends on the implementation of personalized diagnostics and therapeutics. Detailed genomic screening is likely to play a central role in this.

Personalized Medicine has been widely depicted as a striking innovation, that is able to reform the standard approach to disease management, replacing the one-size-fits-all scheme of medicine with a single-patientsized medical intervention. Personalized medicine promoters usually highlight its potential to combine a more effective health-care with costs containment, according to the following rules:

- monitoring of disease risks and more effective prevention;*
- early intervention;*
- selection of optimal therapy;*
- reduction of trial-and-error prescribing and reduction of adverse drug reactions;*
- exclusion of unnecessary drugs;*
- therapeutic drug monitoring and disease progression/remission monitoring;*
- increased patient compliance with therapy.*

But, in spite of expectations, many unsolved practical issues, from technical and scientific to ethical, legal and economic topics, are slowing down the translation of personalized medicine principles into medical practice. Furthermore, wide adoption of personalized strategies also has to deal with the peculiar rules, policy and reimbursement system of each country. Application of Personalized Medicine in the real world seems entangled by the unmet need to develop evidence-based guidelines.

The aim of the meeting, where we are expecting about 150 participants from Italy and Europe, is to discuss with principal key opinion leader about the future prospective of precision medicine and precision oncology and the application in the real world.

19th April

12:00 - 13:00 *Industry Satellite Symposia*

13:00 - 13:30 Lunch

13:30 - 13:45 *Opening and Welcome* - **Giuseppe Curigliano, Paolo Marchetti**
Welcome to the Congress

13:45 - 14:15 *Keynote 1* - **Patricia Lorusso, USA**
Understanding mechanisms of action of modern anticancer drugs

14:15 - 15:45 *Educational session 1* - **Chair: Alberto Bardelli**
Liquid biopsy in the clinic: Is it ready for prime time?

14:15 - 14:35 Clinical utility of liquid biopsy in colorectal cancer
Alberto Bardelli, Milano

14:35 - 14:55 Clinical utility of liquid biopsy in breast cancer
Umberto Malapelle, Napoli

14:55 - 15:15 Incorporating liquid biopsy in clinical practice to stratify the risk
Cristian Rolfo, New York

15:15 - 15:35 European Liquid Biopsy Consortia: From discovery to clinical implementation
Klaus Pantel, Germany

15:35 - 15:45 Q&A

15:45 - 16:30 Coffee break

16:30 - 18:00 *Educational session 2* - **Chairs: Giuseppe Curigliano, Milano - Andrea Botticelli, Roma**
The journey of antibody drug conjugates

16:30 - 16:50 Refining our understanding of ADCs: targeting mutations
Christophe Massard, Rennes, France

16:50 - 17:10 Optimizing the safety of antibody-drug conjugates for the treatment of cancer
Giuseppe Curigliano, Milan, Italy

17:10 - 17:30 Combining ADCs with other agents
Peter Schmid, UK

17:30 - 17:50 Novel antibody drug conjugates and beyond
Patricia Lorusso, Yale, USA

17:50 - 18:00 Q&A

- 08:45 - 10:15** ***Educational session 3*** - Chair: Massimo Di Maio, Turin, Italy
Designing innovative clinical trials
- 08:45 - 09:05** Window of opportunity trials across subtypes
Barbara Pistilli, Paris (France)
- 09:05 - 09:25** Surrogate vs long term endpoint
Massimo Di Maio, Turin, Italy
- 09:25 - 09:45** From maximum tolerated to optimal biological dose
Christophe Le Tourneau, Institute Curie, Paris, France
- 09:45 - 10:05** Decision making process for patients involved in clinical trials
Gabriella Pravettoni, IEO, Milan
- 10:05 - 10:15** Q&A
- 10:15 - 10:45** Coffee break
- 10:45 - 12:15** ***Educational session 4*** - Chairs: Paolo Marchetti, Roma, Italy - Ruggero De Maria, Roma, Italy
Tumor Agnostic Drug Development
- 10:45 - 11:05** Design of next generation precision medicine trials using artificial intelligence
Razelle Kurzrock, USA
- 11:05 - 11:25** Agnostic drug development
Vivek Subbiah, Nashville, USA
- 11:25 - 11:45** Target identification in agnostic drug development
Giancarlo Pruneri, Milan, Italy
- 11:45 - 12:05** Next generation sequencing role in precision medicine
Jeffrey Ross Foundation Medicine, Syracuse, USA
- 12:05 - 12:15** Q&A
- 12:15 - 13:00** Lunch
- 13:00 - 14:00** ***Industry Satellite Symposia***
- 14:10 - 14:40** ***Keynote 2*** - Timothy A. Houston, Texas
Targeting oxidative phosphorylation (OXPHOS) is a rational anticancer strategy

20th April

- 14:40 - 15:00** **Keynote 3** - **Giuseppe Curigliano, Milan, Italy**
Precision Medicine in advanced and early Breast Cancer
- 15:00 - 15:20** **Keynote 4** - **Maurizio Simmaco, Rome, Italy**
Precision Immunotherapy
- 15:20 - 15:40** **Keynote 5** - **Maurizio Simmaco, Rome, Italy**
The pivotal role of functional biochemistry into Precision Medicine
- 15:40 - 16:00** **Keynote 6** - **Nello Martini, Rome, Italy**
Role of the Regulator into precision medicine
- 16:00 - 17:25** **Educational session 5** - **Chairs: Paolo Marchetti, Rome, Italy, Giuseppe Curigliano, Milan, Italy**
Harmonizing Precision Medicine Recommendations
- 16:00 - 16:25** Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers
Fernanda Mosele, Paris, France
- 16:25 - 16:50** Recommendations on clinical reporting of genomics test results
David Tamborero, Stockholm, Sweden
- 16:50 - 17:15** Group Recommendations on the Structure and Quality Indicators for Molecular Tumor Boards in Clinical Practice
Benedikt Westphalen, Munich, Germany
- 17:15 - 17:25** Q&A
- 17:25 - 17:30** Final the evaluation test
- 17:30 - 17:45** Conclusions

Speaker and Chairmen

Bardelli Alberto - Turin (Italy) - IFOM Scientific Director, Principal Investigator Genomics of Cancer and Targeted Therapies, Professor Dept of Oncology, University of Turin

Botticelli Andrea - Rome (Italy) - Associate Professor of Oncology at La Sapienza University of Rome

Curigliano Giuseppe - Milan (Italy) - Full Professor of Medical Oncology, Department of Oncology and Hemato-Oncology, University of Milano. Director Division of Early Drug Development for Innovative Therapies European Institute of Oncology, IRCCS

De Maria Ruggiero - Rome (Italy) - Full Professor of General Pathology at Sacro Cuore University

Di Maio Massimo - Turin (Italy) - Full Professor of Medical Oncology University of Turin

Le Tourneau Christophe - Paris (France) - Head of the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic - Institut Curie

Hamilton Erika - Nashville (USA) - Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute

Kurzrock Razelle - Milwaukee, Wisconsin (USA) - Center Associate Director, Professor of Medicine, Medical College of Wisconsin Cancer Center

Lorusso Patricia - New Haven (USA) - Amy and Joseph Perella Professor of Medicine (Medical Oncology); Chief, Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics Yale Cancer Center University - United States

Malapelle Umberto - Napoli (Italy) - Chief Supervisor of the Predictive Molecular Pathology laboratory of the Department of Public Health of the University of Naples Federico II

Marchetti Paolo - Rome (Italy) - Head of Scientific Department Istituto Dermopatico dell'Immacolata IRCCS

Massard Christophe - Rennes (France) - Medical Oncologist, Head of Cancer Research at Eugène Marquis Cancer Centre in Rennes

Meric-Bernstam Funda - Houston (USA) - Department of Investigational Cancer Therapeutics, Division of Cancer Medicine MD Anderson Cancer Center

Martini Nello - Rome (Italy) - President of the Ricerca e Salute Foundation

Mosele Maria Fernanda - Paris (France) - Department of Medical Oncology, Gustave Roussy, Villejuif

Speaker and Chairmen

Pantel Klaus - Hamburg (Germany) - Chairman of the Institute of Tumour Biology at the University Medical Centre Hamburg-Eppendorf

Pistilli Barbara - Paris (France) - Department of Medical Oncology, Gustave Roussy, Villejuif

Pravettoni Gabriella - Milan (Italy) - Director, Applied Research Division for Cognitive and Psychological Science, IEO

Pruneri Giancarlo - Milan (Italy) - Head, Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale Tumori, Full Professor in Pathology, University of Milan, School of Medicine; Editor-in-Chief Tumori Journal"

Rolfo Christian - New York (USA) - Professor of Medicine, Associate Director of Clinical Research, Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai System & ICAHN School of Medicine, President of the International Society of Liquid Biopsy (ISLB)

Ross Jeffrey - Siracuse (USA) - Medical Director, Foundation Medicine, Departments of Pathology and Urology, Upstate Medical University

Schmid Peter - London (U.K.) - Clinical Director of the Breast Cancer Centre and an honorary consultant medical oncologist at St. Bartholomew's Hospital

Simmaco Maurizio - Rome (Italy) - Full Professor of Molecular Biology La Sapienza University

Tamborero David - Stockholm (Sweden) - Senior Research Scientist Karolinska Institut

Timothy A. Yap - Houston (USA) - Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Subbiah Vivek - Nashville (USA) - Chief, Early-Phase Drug Development at Sarah Cannon Research Institute

Westphalen Christoph Benedikt - Munich (Germany) Head "Molecular Diagnostics and Therapy Programme" and the "Molecular Tumour Board" at the University of Munich, Germany. Medical lead for early phase clinical trials in medical oncology

General Information

Presidents: Giuseppe Curigliano and Paolo Marchetti

Congress Venue:

Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome

CME Provider n. 4795

Didactika S.r.l.

Piazza della Trasfigurazione, 8/a - 00151 Rome

ref. n. 369299

CME Credits: 9,1

This event is open to biologists, medical doctors and surgeons, psychologists.

Disciplines:

Dermatology, Haematology, Gastroenterology, Internal medicine, Oncology, Radiotherapy, Gynaecology, Histology, Biochemistry, Pharmacology and Clinical Toxicology, Clinical Pathology; Medical genetics; General Surgery; Plastic and Reconstructive Surgery; Urology; General Medicine (Family Doctors); Palliative Care.

To obtain the CME credits, the participant should be present for at least 80% of the total duration of the congress, fill in all the forms and pass the final CME test. At the end of the congress, the organizing secretariat will issue a certificate of attendance.


Registration:

Registration is free and necessary. To register for the Congress, please visit us at www.didactika.it or send the registration form by e-mail to: info@didactika.it

Registration includes:

Access to all scientific sessions. Certificate of attendance.

This congress will be held in presence for a maximum of 150 participants.





Provider



Didactika srl



Ne.T.On. S.r.l.
Segreteria Organizzativa